LONG-TERM CIRCADIAN EFFECTS OF SALMETEROL IN ASTHMATIC-CHILDREN TREATED WITH INHALED CORTICOSTEROIDS

被引:48
作者
MEIJER, GG
POSTMA, DD
MULDER, PGH
VANAALDEREN, WMC
机构
[1] UNIV GRONINGEN HOSP,DEPT PULMONOL,9700 RB GRONINGEN,NETHERLANDS
[2] ERASMUS UNIV ROTTERDAM,SCH MED,DEPT BIOSTAT & EPIDEMIOL,ROTTERDAM,NETHERLANDS
关键词
D O I
10.1164/ajrccm.152.6.8520751
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The present study was set up to investigate whether salmeterol in children with asthma already treated with inhaled corticosteroids (ICS) leads to a sustained bronchodilator effect and decreased bronchial responsiveness, both during the day and night. Furthermore, we investigated whether cessation of salmeterol leads to a rebound increase in bronchial responsiveness. Forty children with asthma (aged 7-15 yrs) using ICS participated in a randomized, double-blind, parallel study. They received either twice daily 50 mu g salmeterol or placebo. FEV(1) and provocative concentration of methacholine that caused a 20% fall in FEV(1) (PC20) were measured at 4:00 P.M, and 4:00 A.M. at baseline and after 16 wk. The same measurements were performed at 4:00 P.M. at 8 h after the first dose, and after 1 and 8 wk. After cessation of the study drug, FEV(1) and PC20 Were measured at 12 and 20 h and after 1 wk. Overall mean FEV(1) from 1 to 16 wk of treatment was significantly higher in the salmeterol group than in the placebo group (difference, 4.9 +/- 2.0%, p = 0.01). Evolution in time of FEV(1) did not differ significantly between the two groups (p = 0.09). Overall mean PC20 from 1 to 16 wk of treatment was not significantly higher with salmeterol than with placebo (difference, 0.7 +/- 0.4 doubling dose [DD] p = 0.07); evolution in time of PC20 did not differ significantly between the two groups (p = 0.58). The increase of PC20 8 h after the start of the study was significantly higher with salmeterol than with placebo (1.9 +/-:0.3 DD versus 0.7 +/- 0.3 DD, p < 0.01); significance disappeared at 1 wk. At 16 wk, the circadian variation (day minus night value) in FEV(1) was significantly smaller with salmeterol than with placebo (-0.9 +/- 0.9% versus 2.2 +/- 1.0%, p = 0.03); this was not the case for PC20. No rebound worsening of FEV(1) or PC20 methacholine was observed after cessation of salmeterol. Sixteen weeks of treatment with salmeterol given to children with asthma on regular ICS leads to a sustained bronchodilator effect and improved circadian variation in airway diameter. The initial significant decrease in bronchial responsiveness dropped below significance after 1 wk, and no overall additive beneficial effect of salmeterol on bronchial responsiveness was present. Finally, cessation of salmeterol after 4 mo of treatment does not lead to a rebound increase in bronchial responsiveness in children with asthma treated with inhaled ICS.
引用
收藏
页码:1887 / 1892
页数:6
相关论文
共 31 条
[1]   EFFECT ON AIRWAY RESPONSIVENESS OF 6 WEEKS TREATMENT WITH SALMETEROL [J].
BEACH, JR ;
YOUNG, CL ;
HARKAWAT, R ;
GARDINER, PV ;
AVERY, AJ ;
COWARD, GA ;
WALTERS, EH ;
HENDRICK, DJ .
PULMONARY PHARMACOLOGY, 1993, 6 (02) :155-157
[2]   CHANGES IN METHACHOLINE-INDUCED BRONCHOCONSTRICTION WITH THE LONG-ACTING BETA(2) AGONIST SALMETEROL IN MILD-TO-MODERATE ASTHMATIC-PATIENTS [J].
BOOTH, H ;
FISHWICK, K ;
HARKAWAT, R ;
DEVEREUX, G ;
HENDRICK, DJ ;
WALTERS, EH .
THORAX, 1993, 48 (11) :1121-1124
[3]   SALMETEROL COMPARED WITH SLOW-RELEASE TERBUTALINE IN NOCTURNAL ASTHMA - A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, SEQUENTIAL CLINICAL-TRIAL [J].
BRAMBILLA, C ;
CHASTANG, C ;
GEORGES, D ;
BERTIN, L ;
DESFOUGERES, JL ;
ANTIPHON, P ;
AUBIER, M ;
BARBIER, R ;
BELLVERT, P ;
BLANCHON, F ;
BONNAMOUR, C ;
BOUTRY, D ;
CABRERA, J ;
CARLES, P ;
CHAMAS, M ;
CHARPIN, D ;
CHAVAILLON, JM ;
CLAVIER, J ;
COSTE, E ;
CROXO, C ;
DELECLUSE, P ;
DENNEWALD, G ;
DERENNE, JP ;
EPSTEIN, M ;
FIAUD, JP ;
GAILLARD, JR ;
GAUCHER, L ;
GREILLIER, P ;
GRIGNET, JP ;
GROSCLAUDE, M ;
GRUNCHEC, N ;
GUERIN, P ;
GUILLAIS, P ;
KRAI, D ;
LAVANDIER, M ;
LEBAS, FX ;
LECOCGUIC, Y ;
LEGENDRE, M ;
LEGOFF, C ;
LUGASSY, D ;
MAFFRE, JP ;
MARTIN, M ;
MATHIEU, M ;
MEEKEL, P ;
MORALES, R ;
MULLER, D ;
PERRINFAYOLLE, M ;
PRUDHOMME, A ;
REMAN, A ;
STERN, M .
ALLERGY, 1994, 49 (06) :421-426
[4]  
BRITTON MG, 1992, EUR RESPIR J, V5, P1062
[5]   LONG-TERM EFFECTS OF A LONG-ACTING BETA-2-ADRENOCEPTOR AGONIST, SALMETEROL, ON AIRWAY HYPERRESPONSIVENESS IN PATIENTS WITH MILD ASTHMA [J].
CHEUNG, D ;
TIMMERS, MC ;
ZWINDERMAN, AH ;
BEL, EH ;
DIJKMAN, JH ;
STERK, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (17) :1198-1203
[6]   SALMETEROL XINAFOATE AS MAINTENANCE THERAPY COMPARED WITH ALBUTEROL IN PATIENTS WITH ASTHMA [J].
DALONZO, GE ;
NATHAN, RA ;
HENOCHOWICZ, S ;
MORRIS, RJ ;
RATNER, P ;
RENNARD, SI .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (18) :1412-1416
[7]   MORBIDITY IN NOCTURNAL ASTHMA - SLEEP QUALITY AND DAYTIME COGNITIVE PERFORMANCE [J].
FITZPATRICK, MF ;
ENGLEMAN, H ;
WHYTE, KF ;
DEARY, IJ ;
SHAPIRO, CM ;
DOUGLAS, NJ .
THORAX, 1991, 46 (08) :569-573
[8]   SALMETEROL IN NOCTURNAL ASTHMA - A DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF A LONG-ACTING INHALED BETA-2 AGONIST [J].
FITZPATRICK, MF ;
MACKAY, T ;
DRIVER, H ;
DOUGLAS, NJ .
BRITISH MEDICAL JOURNAL, 1990, 301 (6765) :1365-1368
[9]   PREVENTION OF EXERCISE INDUCED ASTHMA BY INHALED SALMETEROL XINAFOATE [J].
GREEN, CP ;
PRICE, JF .
ARCHIVES OF DISEASE IN CHILDHOOD, 1992, 67 (08) :1014-1017
[10]   ADDED SALMETEROL VERSUS HIGHER-DOSE CORTICOSTEROID IN ASTHMA PATIENTS WITH SYMPTOMS ON EXISTING INHALED CORTICOSTEROID [J].
GREENING, AP ;
IND, PW ;
NORTHFIELD, M ;
SHAW, G .
LANCET, 1994, 344 (8917) :219-224